These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 31146197)

  • 1. 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.
    Sobhy MK; Mowafy S; Lasheen DS; Farag NA; Abouzid KAM
    Bioorg Chem; 2019 Aug; 89():102988. PubMed ID: 31146197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent thieno[2,3-d]pyrimidine VEGFR-2 inhibitors: Design, synthesis and enzyme inhibitory evaluation supported by molecular dynamics simulations.
    Elrazaz EZ; Serya RAT; Ismail NSM; Albohy A; Abou El Ella DA; Abouzid KAM
    Bioorg Chem; 2021 Aug; 113():105019. PubMed ID: 34091286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
    Bhojwani HR; Joshi UJ
    Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
    Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
    Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
    Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
    Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer.
    Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM
    Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
    Sun W; Hu S; Fang S; Yan H
    Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAF
    Wang Y; Wan S; Li Z; Fu Y; Wang G; Zhang J; Wu X
    Eur J Med Chem; 2018 Jul; 155():210-228. PubMed ID: 29886324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
    Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
    Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
    Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M
    Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of novel furan, furo[2,3-d]pyrimidine and furo[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives as potential VEGFR-2 inhibitors.
    Abd El-Mageed MMA; Eissa AAM; Farag AE; Osman EEA
    Bioorg Chem; 2021 Nov; 116():105336. PubMed ID: 34530235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
    Adel M; Serya RAT; Lasheen DS; Abouzid KAM
    Bioorg Chem; 2018 Dec; 81():612-629. PubMed ID: 30248512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl)phthalazine derivatives.
    Eldehna WM; Abou-Seri SM; El Kerdawy AM; Ayyad RR; Hamdy AM; Ghabbour HA; Ali MM; Abou El Ella DA
    Eur J Med Chem; 2016 May; 113():50-62. PubMed ID: 26922228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation.
    Abdel-Mohsen HT; Girgis AS; Mahmoud AEE; Ali MM; El Diwani HI
    Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900089. PubMed ID: 31463965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of novel oxazolo[5,4-d]pyrimidines as potent VEGFR-2 inhibitors.
    Deng YH; Xu D; Su YX; Cheng YJ; Yang YL; Wang XY; Zhang J; You QD; Sun LP
    Chem Biodivers; 2015 Apr; 12(4):528-37. PubMed ID: 25879498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles.
    Abdel-Mohsen HT; Abdullaziz MA; Kerdawy AME; Ragab FAF; Flanagan KJ; Mahmoud AEE; Ali MM; Diwani HIE; Senge MO
    Molecules; 2020 Feb; 25(4):. PubMed ID: 32053964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of biphenyl-based VEGFR-2 inhibitors. Part 3: design, synthesis and 3D-QSAR studies.
    Lu W; Li P; Shan Y; Su P; Wang J; Shi Y; Zhang J
    Bioorg Med Chem; 2015 Mar; 23(5):1044-54. PubMed ID: 25637123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacophore based 3D-QSAR modeling and free energy analysis of VEGFR-2 inhibitors.
    Rajagopalan M; Balasubramanian S; Ramaswamy A; Mathur PP
    J Enzyme Inhib Med Chem; 2013 Dec; 28(6):1236-46. PubMed ID: 23061928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.